EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma

Xuechun Wang, Yujing Qin iD, Loan D Duong, Minzhi Liang iD, Adrian Chao iD, Rossella Parrotta, Yaoyin Li, Paresh Kumar Purohit, Yihao Fang, Guoqiang Liu, Jianping He iD, Jiling Wen und 8 weitere

Proceedings of the National Academy of Sciences · 07.07.2026 · 123 (27)

DOI: 10.1073/pnas.2535452123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 01.07.2026. Verfasst von Xuechun Wang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame,…. Hauptthemen laut MEDLINE: TNF-Related Apoptosis-Inducing Ligand, Carcinoma, Renal Cell, Von Hippel-Lindau Tumor Suppressor Protein, Kidney Neoplasms. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, University of Notre Dame (ND), Boler Family Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive subtype of kidney cancer. Loss of von Hippel–Lindau (VHL) and the consequent activation of hypoxia-inducible factor-α (HIFα, especially HIF2α) plays an essential role in ccRCC initiation and progression. The VHL–HIF2α axis as the main driver for ccRCC may present specific opportunities to control the disease by cotargeting HIF2α with belzutifan and another vulnerability. This study elucidates the synthetic essentiality of TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) in VHL-deficient ccRCC. Upregulated in ccRCC in a VHL–HIF2α-dependent manner, TRAIL is selectively essential in ccRCC cells, promoting cell proliferation by activating the p38 MAPK pathway and facilitating G1/S phase transition. Depletion of endogenous TRAIL or inhibition of HIF2α with belzutifan sensitizes ccRCC cell and tumor models to recombinant TRAIL, presenting a promising avenue for combination therapy in ccRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TNF-Related Apoptosis-Inducing LigandCarcinoma, Renal CellVon Hippel-Lindau Tumor Suppressor ProteinKidney NeoplasmsHumansEndothelial PAS Domain-Containing Protein 1Basic Helix-Loop-Helix ProteinsCell Line, TumorAnimalsCell ProliferationMicep38 Mitogen-Activated Protein Kinases

Stichwörter der Autor:innen

HIF2αTRAILVHLbelzutifanrenal cell carcinoma

Substanzen

TNF-Related Apoptosis-Inducing LigandVon Hippel-Lindau Tumor Suppressor ProteinEndothelial PAS Domain-Containing Protein 1Basic Helix-Loop-Helix ProteinsVHL protein, humanTNFSF10 protein, humanp38 Mitogen-Activated Protein Kinases

Autor:innen und Institutionen

  • Department of Biological Sciences, Boler-Parseghian Center for Rare Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556.
  • Integrated Biomedical Sciences Graduate Program, College of Science, University of Notre Dame, Notre Dame, IN 46556.
  • School of Chemical and Biological Sciences, University of Galway, Galway H91 TK33, Ireland.
  • Department of Applied and Computational Mathematics and Statistics, University of Notre Dame, Notre Dame, IN 46556.
  • Cancer Biology & Microenvironment Program, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN 46202.

ORCID-Profile: Yujing Qin, Minzhi Liang, Adrian Chao, Jianping He, Yan Liu, Nipuni Barupala, Zachary T Schafer, Eva Szegezdi, Xin Lu

Förderung

  • NCI NIH HHS
  • University of Notre Dame (ND)
  • Boler Family Foundation
  • HHS | NIH (NIH)
  • VHL Alliance (VHLA)
  • U.S. Department of Defense (DOD)

Zitieren

APA

Wang, X., Qin, Y., Duong, L. D., Liang, M., Chao, A., Parrotta, R., Li, Y., Purohit, P. K., Fang, Y., Liu, G., He, J., Wen, J., Liu, Y., Zhang, Y., Zhao, J., Barupala, N., Schafer, Z. T., Lu, X., Szegezdi, E., & Lu, X. (2026). Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma. Proceedings of the National Academy of Sciences, 123(27). https://doi.org/10.1073/pnas.2535452123

Vancouver

Wang X, Qin Y, Duong LD, Liang M, Chao A, Parrotta R, et al. Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma. Proceedings of the National Academy of Sciences. 2026;123(27). doi:10.1073/pnas.2535452123

BibTeX
@article{Wang2026,
  author = {Wang, Xuechun and Qin, Yujing and Duong, Loan D and Liang, Minzhi and Chao, Adrian and Parrotta, Rossella and Li, Yaoyin and Purohit, Paresh Kumar and Fang, Yihao and Liu, Guoqiang and He, Jianping and Wen, Jiling and Liu, Yan and Zhang, Yuting and Zhao, Junling and Barupala, Nipuni and Schafer, Zachary T and Lu, Xuemin and Szegezdi, Eva and Lu, Xin},
  title = {Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {27},
  doi = {10.1073/pnas.2535452123}
}
Kostenlos starten →